CoChat
Sign Up
Cited by 93

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Potential Roles of Exosomal MicroRNAs as Diagnostic Biomarkers and Therapeutic Application in Alzheimer’s Disease

Chen, Jian-jiao, Zhao, Bin, Zhao, Jie, Li, Shao·2017·Neural Plasticity
DOI 10.1155/2017/7027380PMC PMC5523215
Open this paper in CoChat — free account

Abstract

Exosomes are bilipid layer-enclosed vesicles derived from endosomes and are released from neural cells. They contain a diversity of proteins, mRNAs, and microRNAs (miRNAs) that are delivered to neighboring cells and/or are transported to distant sites. miRNAs released from exosomes appear to be associated with multiple neurodegenerative conditions linking to Alzheimer’s disease (AD) which is marked by hyperphosphorylated tau proteins and accumulation of A β plaques. Exciting findings reveal that miRNAs released from exosomes modulate the expression and function of amyloid precursor proteins (APP) and tau proteins. These open up the possibility that dysfunctional exosomal miRNAs may influence AD progression. In addition, it has been confirmed that the interaction between miRNAs released by exosomes and Toll-like receptors (TLR) initiates inflammation. In exosome support-deprived neurons, exosomal miRNAs may regulate neuroplasticity to relieve neurological damage. In this review, we summarize the literature on the function of exosomal miRNAs in AD pathology, the potential of these miRNAs as diagnostic biomarkers in AD, and the use of exosomes in the delivery of miRNAs which may lead to major advances in the field of macromolecular drug delivery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2017/7027380

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The biogenesis pathway of exosomal miRNA and composition of exosome. Canonical miRNAs are initially transcribed from long (41 kb) endogenous precursors called primary miRNAs that are driven by RNA pol II promoters and cleaved by microprocessor, a multiprotein complex formed by the RNase type III Drosha (the Drosophila homolog of RNASEN in humans) and the protein DGCR8 (Di George Syndrome Critical Region 8). A hairpin structure (now known as pre-miRNA) with 60–80 nucleotides in length, which bears a two-nucleotide overhang at the 3′ end that is a mark left by the Drosha processing, is released in this step. Within neuronal nuclei, pri- and pre-miRNA may be stabilized by 3′-terminal adenylation performed by PAPD4. After recognizing the precursors by their overhangs, GTPase-dependent Ran-Exp5 complex exports the pre-miRNAs out of the nucleus to the cytoplasm. An alternative pathway needs splicing out of the miRNAs from introns located in other genes, then further lariat processing, and finally proper folding into a pre-miRNA structure. In the cytoplasm, cleavage of the pre-miRNAs takes place once they have been loaded onto the Dicer-TRBP (TAR-RNA binding protein) complex, which removes the loop from the pre-miRNA to produce a dsRNA duplex that contains both the mature miRNA (or leader strand) and the so-called passenger strand. The Dicer-TRBP complex rapidly transfers the duplex to the miRISC (miRNA-RNAi-induced silencing complex), which contains AGO (Argonaute proteins) as its core. The HSP90/HSC70 chaperone complex participates in the process. In the miRISC, the passenger strand is degraded by an unidentified mechanism, leaving a mature miRISC loaded with a fully mature single-stranded miRNA (19–22 nt) to bind canonically to non-fully complementary mRNA targets at their 3′ untranslated regions (UTR). Alternatively, pri-miRNAs and miRNA may be loaded with proteins of RNA transport granules. These molecules are then transported to specific neuronal compartments, where mature or precursor miRNAs are enveloped in exosomes to be released elsewhere. Mature miRNAs are sorted into exosomes via four potential mechanisms: (1) the neutral sphingomyelinase 2- (nSMase2-) dependent pathway; (2) the miRNA motif and sumoylated heterogeneous nuclear ribonucleoprotein- (hnRNP-) dependent pathway; (3) the 3′-end of the miRNA sequence-dependent pathway; and (4) the miRNA-induced silencing complex- (miRISC-) related pathway (not shown).
Figure 1 The biogenesis pathway of exosomal miRNA and composition of exosome. Canonical miRNAs are initially transcribed from long (41 kb) endogenous precursors called primary miRNAs that are driven by RNA pol II promoters and cleaved by microprocessor, a multiprotein complex formed by the RNase type III Drosha (the Drosophila homolog of RNASEN in humans) and the protein DGCR8 (Di George Syndrome Critical Region 8). A hairpin structure (now known as pre-miRNA) with 60–80 nucleotides in length, which bears a two-nucleotide overhang at the 3′ end that is a mark left by the Drosha processing, is released in this step. Within neuronal nuclei, pri- and pre-miRNA may be stabilized by 3′-terminal adenylation performed by PAPD4. After recognizing the precursors by their overhangs, GTPase-dependent Ran-Exp5 complex exports the pre-miRNAs out of the nucleus to the cytoplasm. An alternative pathway needs splicing out of the miRNAs from introns located in other genes, then further lariat processing, and finally proper folding into a pre-miRNA structure. In the cytoplasm, cleavage of the pre-miRNAs takes place once they have been loaded onto the Dicer-TRBP (TAR-RNA binding protein) complex, which removes the loop from the pre-miRNA to produce a dsRNA duplex that contains both the mature miRNA (or leader strand) and the so-called passenger strand. The Dicer-TRBP complex rapidly transfers the duplex to the miRISC (miRNA-RNAi-induced silencing complex), which contains AGO (Argonaute proteins) as its core. The HSP90/HSC70 chaperone complex participates in the process. In the miRISC, the passenger strand is degraded by an unidentified mechanism, leaving a mature miRISC loaded with a fully mature single-stranded miRNA (19–22 nt) to bind canonically to non-fully complementary mRNA targets at their 3′ untranslated regions (UTR). Alternatively, pri-miRNAs and miRNA may be loaded with proteins of RNA transport granules. These molecules are then transported to specific neuronal compartments, where mature or precursor miRNAs are enveloped in exosomes to be released elsewhere. Mature miRNAs are sorted into exosomes via four potential mechanisms: (1) the neutral sphingomyelinase 2- (nSMase2-) dependent pathway; (2) the miRNA motif and sumoylated heterogeneous nuclear ribonucleoprotein- (hnRNP-) dependent pathway; (3) the 3′-end of the miRNA sequence-dependent pathway; and (4) the miRNA-induced silencing complex- (miRISC-) related pathway (not shown).CC BY · PubMed Central
Figure 2 Neural cell types and their Toll-like receptor (TLR) expression. Protein profile for TLR3, 4, 7, and 9 has been reported in different neural phenotypes from humans; only TLR2 protein profile is detected in human oligodendrocytes; TLR3-4 protein accumulation is found in human astrocytes; human microglia contains TLR1–4 protein profile.
Figure 2 Neural cell types and their Toll-like receptor (TLR) expression. Protein profile for TLR3, 4, 7, and 9 has been reported in different neural phenotypes from humans; only TLR2 protein profile is detected in human oligodendrocytes; TLR3-4 protein accumulation is found in human astrocytes; human microglia contains TLR1–4 protein profile.CC BY · PubMed Central
Figure 3 Schematic representation of production, harvest, and readministration of engineering modified exosomes for gene delivery. To acquire enough immunologically inert exosomes, harvest cells like hemopoietic progenitors and osteocytes are used as the source cell. As immature dendritic cells produce a lot of exosomes devoid of T-cell activators such as MHC-II and CD86, it could be selected as the source cell. Targeting peptides expressing plasmids (e.g., RVG (rabies virus glycoprotein)) were transfected into the source cells to get exosomes with the ability of specifically binding to neural cells. Therapeutic nucleic acids can be introduced into the modified exosomes by electroporation method. Following intravenous injection, exosomes encapsulating nucleic acids could be found within the central nervous system.
Figure 3 Schematic representation of production, harvest, and readministration of engineering modified exosomes for gene delivery. To acquire enough immunologically inert exosomes, harvest cells like hemopoietic progenitors and osteocytes are used as the source cell. As immature dendritic cells produce a lot of exosomes devoid of T-cell activators such as MHC-II and CD86, it could be selected as the source cell. Targeting peptides expressing plasmids (e.g., RVG (rabies virus glycoprotein)) were transfected into the source cells to get exosomes with the ability of specifically binding to neural cells. Therapeutic nucleic acids can be introduced into the modified exosomes by electroporation method. Following intravenous injection, exosomes encapsulating nucleic acids could be found within the central nervous system.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 81

  1. 10.1016/j.trsl.2014.05.006 · DOI
  2. 10.1016/S1474-4422(13)70044-9 · DOI · Paper page
  3. 10.3892/mmr.2014.2484 · DOI · Paper page
  4. 2015, PloS One, 10
  5. 10.18632/oncotarget.6158 · DOI · Paper page
  6. 2015, Molecular Psychiatry, 20, 1188, 10.1038/mp.2014.127 · DOI · Paper page
  7. 10.3389/fimmu.2015.00203 · DOI
  8. 10.1016/j.febslet.2014.11.027 · DOI
  9. 10.1038/nbt.1807 · DOI · Paper page
  10. 10.1038/nbt.1830 · DOI · Paper page
  11. 2015, Disease Markers, 2015
  12. 10.1016/j.arr.2014.02.006 · DOI
  13. 10.1016/j.gpb.2015.02.001 · DOI · Paper page
  14. 10.1172/JCI78421 · DOI · Paper page
  15. 10.1159/000430356 · DOI
  16. 10.1016/j.brainres.2015.07.022 · DOI
  17. 10.1007/s12035-013-8603-7 · DOI
  18. 10.3389/fimmu.2014.00442 · DOI
  19. 10.1242/jcs.128868 · DOI
  20. 10.1038/cr.2015.29 · DOI
  21. 10.1016/j.bcp.2011.12.037 · DOI
  22. 10.1038/ncb0309-228 · DOI
  23. 10.1038/ncb1929 · DOI
  24. 10.1074/jbc.M112.446831 · DOI
  25. 10.1038/ncomms3980 · DOI · Paper page
  26. 10.1016/j.celrep.2014.08.027 · DOI · Paper page
  27. 10.1186/1471-2164-13-357 · DOI
  28. 2013, PloS One, 8
  29. 10.1242/dev.127209 · DOI
  30. 2014, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 369, 1652
  31. 10.1523/JNEUROSCI.1165-14.2014 · DOI
  32. 10.1093/nar/gku594 · DOI · Paper page
  33. 10.1038/cddis.2012.114 · DOI
  34. 10.1016/j.jmb.2015.09.019 · DOI
  35. 10.1016/j.jneuroim.2013.10.014 · DOI
  36. 10.1002/stem.1409 · DOI
  37. 2014, PloS One, 9
  38. 2015, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 370, 1672
  39. 10.1074/jbc.M112.410944 · DOI · Paper page
  40. 10.1182/blood-2011-08-374793 · DOI
  41. 2011, Molecular and Cellular Pharmacology, 3, 83
  42. 2015, International Journal of Clinical and Experimental Pathology, 8, 1565
  43. 10.3892/mmr.2015.3728 · DOI
  44. 10.1016/j.bbrc.2010.12.053 · DOI
  45. 2015, PloS One, 10
  46. 10.1523/JNEUROSCI.4571-15.2016 · DOI · Paper page
  47. 10.1111/jnc.13212 · DOI
  48. 10.1093/hmg/ddq311 · DOI
  49. 10.1007/s11011-013-9434-y · DOI
  50. 2012, PloS One, 7
  51. 2010, Proceedings of the National Academy of Sciences of the United States of America, 107, 6328, 10.1073/pnas.0914843107 · DOI
  52. 2015, PloS One, 10
  53. 2015, Turkish Journal of Medical Sciences, 45, 1082
  54. 10.1002/jnr.22767 · DOI
  55. 10.1111/jnc.13101 · DOI
  56. 10.1038/srep06824 · DOI
  57. 10.4049/jimmunol.1001241 · DOI
  58. 2014, BioMed Research International, 2014
  59. 10.1038/nn.3113 · DOI · Paper page
  60. 2012, PloS One, 7
  61. 10.1080/15287394.2011.618973 · DOI
  62. 10.3892/mmr.2015.3968 · DOI
  63. 10.3171/2014.11.JNS14770 · DOI · Paper page
  64. 10.1038/jcbfm.2013.152 · DOI
  65. 10.1002/stem.1129 · DOI
  66. 10.1002/ana.24235 · DOI · Paper page
  67. 10.1002/glia.22606 · DOI
  68. 2015, PloS One, 10
  69. 10.1093/nar/gks832 · DOI
  70. 10.1016/j.semcdb.2014.11.004 · DOI · Paper page
  71. 10.1016/j.neurobiolaging.2006.05.016 · DOI · Paper page
  72. 2013, Methods in Molecular Biology, 1024, 19, 10.1007/978-1-62703-453-1_3 · DOI
  73. 10.1186/2045-8118-10-4 · DOI
  74. 2013, PloS One, 8
  75. 10.1159/000343452 · DOI
  76. 2012, International Journal of Biochemistry and Molecular Biology, 3, 365
  77. 10.3389/fgene.2013.00150 · DOI
  78. 10.1016/j.addr.2012.06.014 · DOI
  79. 2014, Advances in Experimental Medicine and Biology, 801, 259, 10.1007/978-1-4614-3209-8_33 · DOI
  80. 2007, Proceedings of the National Academy of Sciences of the United States of America, 104, 234, 10.1073/pnas.0609665104 · DOI
  81. 10.1007/s12975-010-0033-5 · DOI

Cited by

Sorted by citations

See all 93

Metadata

Authors
Chen, J.-J., Zhao, B., Zhao, J., & Li, S.
Affiliations
  • Department of Physiology, Liaoning Provincial Key Laboratory of Cerebral Diseases, Dalian Medical University, Dalian City, Liaoning Province 116044, China
  • Technology Centre of Target-Based Nature Products for Prevention and Treatment of Aging-Related Neurodegeneration, Dalian Medical University, Dalian, Liaoning, China
ORCID
Venue
Neural Plasticity
Publisher
Wiley
Published
2017
Volume
2017
Pages
1-12
ISSN
  • 2090-5904
  • 1687-5443
DOI
10.1155/2017/7027380
PMC
PMC5523215
Cited by
93
References
8
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)
Funders
National Natural Science Foundation of China (81571061, 81671061, 81371223, 81371437)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review